At AMCP Nexus 2025, Autumn D. Zuckerman, PharmD, BCPS, CSP, joined by Amy Niles, MBA, and Ashira Vantrees, Esq., unpacked 3 cost-shifting strategies that are reshaping access to specialty medicines: copay accumulators, copay maximizers, and...
At AMCP Nexus 2025, Autumn D. Zuckerman, PharmD, BCPS, CSP, joined by Amy Niles, MBA, and Ashira Vantrees, Esq., unpacked 3 cost-shifting strategies that are reshaping access to specialty medicines: copay accumulators, copay maximizers, and...
At Asembia 2025, experts from AcariaHealth detailed how strategic management of free drug programs can optimize outcomes for manufacturers and patients alike, while adapting to evolving regulatory and payer environments.
At Asembia 2025, experts from AcariaHealth detailed how strategic management of free drug programs can optimize outcomes for manufacturers and patients alike, while adapting to evolving regulatory and payer environments.
As oncology treatments grow more advanced and expensive, a panel of experts at AMCP 2025 reveal how managed care strategies are evolving to ensure both cost control and high-quality patient outcomes.
As oncology treatments grow more advanced and expensive, a panel of experts at AMCP 2025 reveal how managed care strategies are evolving to ensure both cost control and high-quality patient outcomes.
Explore the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act with AMCP Nexus 2024 session speakers, addressing successes and challenges faced by stakeholders as they prepare for significant changes ahead.
Explore the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act with AMCP Nexus 2024 session speakers, addressing successes and challenges faced by stakeholders as they prepare for significant changes ahead.
Researchers at AMCP Nexus 2024 explored the cost-effectiveness of Midomafetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) in US health care settings, with findings suggesting it may be a more cost-effective...
Researchers at AMCP Nexus 2024 explored the cost-effectiveness of Midomafetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) in US health care settings, with findings suggesting it may be a more cost-effective...
Multigene panel testing can increase eligibility for targeted therapy in lung and colorectal cancer patients while only representing a small portion of total care costs according to research presented at AMCP Nexus 2024.
Multigene panel testing can increase eligibility for targeted therapy in lung and colorectal cancer patients while only representing a small portion of total care costs according to research presented at AMCP Nexus 2024.
In July 2024, the Federal Trade Commission (FTC) published an interim report discussing the impact that pharmacy benefit managers (PBMs) have on the accessibility and affordability of drugs in the US. The report was issued as part of an...
In July 2024, the Federal Trade Commission (FTC) published an interim report discussing the impact that pharmacy benefit managers (PBMs) have on the accessibility and affordability of drugs in the US. The report was issued as part of an...
Matt Dickinson, PharmD, MBA, Alnylam Pharmaceuticals, led a panel to highlight payer strategies for managing rare and specialty disease products and how they continue to evolve based on Alnylam Pharmaceuticals’ 2023 Rare and Specialty Trend...
Matt Dickinson, PharmD, MBA, Alnylam Pharmaceuticals, led a panel to highlight payer strategies for managing rare and specialty disease products and how they continue to evolve based on Alnylam Pharmaceuticals’ 2023 Rare and Specialty Trend...
The rapid pace of innovation, rising costs of prescription drugs, and the need for transparency to ensure access and affordability in the pharmaceutical industry are discussed in a session at Asembia 2024.
The rapid pace of innovation, rising costs of prescription drugs, and the need for transparency to ensure access and affordability in the pharmaceutical industry are discussed in a session at Asembia 2024.
“These data show that the burden of care for NASH is substantial, and compared with those without progression, the annual costs per person with progression are at least 2-fold higher, with the gap increasing over time,” said researchers that...
“These data show that the burden of care for NASH is substantial, and compared with those without progression, the annual costs per person with progression are at least 2-fold higher, with the gap increasing over time,” said researchers that...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
